Results 221 to 230 of about 58,284 (283)

Evaluation of Xpert MTB/XDR and Deeplex Myc-TB for the Rapid Detection of Drug Resistance in <i>Mycobacterium tuberculosis</i>. [PDF]

Int J Microbiol
Park M, Solanki P, McHugh TD, Kon OM, Satta G.   +4 more
europepmc   +1 more source

Naturally occurring dinactin targets cpsA protein and kills Mycobacterium tuberculosis by disrupting the proton motive force. [PDF]

Commun Biol
Wang G, Dong W, Bai Y, Li Y, Lu H, Lu W, Wang C, Tang J, Li P, Wang R, Wang X, Chen H, Tan C.   +12 more
europepmc   +1 more source

Antibiotic-associated encephalopathy: A retrospective pharmacovigilance study based on 21 years of data from the US FDA Adverse Event Reporting System. [PDF]

Medicine (Baltimore)
Wang H, Jiang H, Yang H, Tang J, Zhang J.   +4 more
europepmc   +1 more source

Factors associated with completion of 6 months of isoniazid preventive therapy among under-five children exposed to tuberculosis patients in Blantyre, Malawi. [PDF]

J Public Health Afr
Mzama GT, Kaswaswa K, Chirwa T, Kagura J, Ibisomi L.   +4 more
europepmc   +1 more source

Correction: Germ-line exon 21 EGFR V831H mutation in advanced NSCLC resistance to almonertinib: a case report. [PDF]

Front Oncol
Cai D, Lou J, Zhu Y, Wang Y.
europepmc   +1 more source

Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients. [PDF]

Int J Mol Sci
Makhon A, Fuchs S, Rubinstein M, Brodsky M, Dveyrin Z, Tejman-Yarden N, Losev Y.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Isoniazid Interactions

Southern Medical Journal, 1985
Isoniazid is an antituberculous drug that is usually administered for nine to 12 months. The potential for clinically important interactions exists because this drug is a potent inhibitor of drug metabolism. Studies and case reports have shown that isoniazid inhibits the metabolism of several drugs, including phenytoin, carbamazepine, anticoagulants ...
A M, Baciewicz, T H, Self
openaire   +2 more sources

Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid

Journal of Antimicrobial Chemotherapy, 2018
OBJECTIVES: To describe the pharmacokinetics of isoniazid and acetyl-isoniazid in TB/HIV-coinfected patients, and assess the effects of efavirenz co-administration and a 50% increase in the dose of rifampicin on the pharmacokinetic parameters of ...
Maxwell Chirehwa, Helen Mcilleron, Lubbe Wiesner   +2 more
exaly   +2 more sources